108 related articles for article (PubMed ID: 2274929)
21. [Effect of recombinant urokinase activator plasminogen on the platelet aggregation and increase of the intracellular calcium level].
Zubkov AV; Bushueva TL; Minashkin MM; Gurskiĭ IaG; Men'shikov MIu
Biull Eksp Biol Med; 1999 Sep; 128(9):339-43. PubMed ID: 10560061
[No Abstract] [Full Text] [Related]
22. L-carnitine inhibits a subset of platelet activation responses in chronic uraemia.
Bonomini M; Sirolli V; Dottori S; Amoroso L; Di Liberato L; Arduini A
Nephrol Dial Transplant; 2007 Sep; 22(9):2623-9. PubMed ID: 17478491
[TBL] [Abstract][Full Text] [Related]
23. Haemorheological changes in uraemic children in response to erythropoietin treatment.
Böhler T; Leo A; Linderkamp O; Braun A; Schärer K
Nephrol Dial Transplant; 1993; 8(2):140-5. PubMed ID: 8384334
[TBL] [Abstract][Full Text] [Related]
24. Changes in sensitivity to angiotensin II in platelets.
Haller H; Lüdersdorf M; Lenz T; Distler A; Philipp T
J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S44-7. PubMed ID: 2455138
[TBL] [Abstract][Full Text] [Related]
25. Prostaglandin A1 inhibits increases in intracellular calcium concentration, TXA(2) production and platelet activation.
Zhu Y; Gu ZL; Liang ZQ; Zhang HL; Qin ZH
Acta Pharmacol Sin; 2006 May; 27(5):549-54. PubMed ID: 16626509
[TBL] [Abstract][Full Text] [Related]
26. [Evaluation of platelet function during treatment with recombinant human erythropoietin (r-HuEPO) in patients hemodialyzed and dialyzed peritoneally].
Janicka L; Majdan M; Dmoszyńska A; Ksiazek A; Berger B; Baranowska E
Wiad Lek; 1993 Oct; 46(19-20):756-60. PubMed ID: 7975620
[TBL] [Abstract][Full Text] [Related]
27. Intradialytic and postdialytic platelet activation, increased platelet phosphatidylserine exposure and ultrastructural changes in platelets in children with chronic uremia.
Elshamaa MF; Elghoroury EA; Helmy A
Blood Coagul Fibrinolysis; 2009 Jun; 20(4):230-9. PubMed ID: 19521197
[TBL] [Abstract][Full Text] [Related]
28. Studies on platelet aggregation using the Born method in normal and uraemic dogs.
Mischke R; Schulze U
Vet J; 2004 Nov; 168(3):270-5. PubMed ID: 15501144
[TBL] [Abstract][Full Text] [Related]
29. [Changes of cytoplasmic calcium and magnesium concentration and calcium distribution in human platelets caused by thrombin].
Zhu MY; Zhu MS
Sheng Li Xue Bao; 1995 Feb; 47(1):73-9. PubMed ID: 7540318
[TBL] [Abstract][Full Text] [Related]
30. Effects of nicardipine on blood pressure and platelet cytosolic free calcium concentration in SHR.
Baba A; Fukuda K; Kuchii M; Hano T; Nishio I; Masuyama Y
J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S70-1. PubMed ID: 2455145
[TBL] [Abstract][Full Text] [Related]
31. Erythropoietin and uremic platelet aggregation in vivo and in vitro.
Malyszko JS; Malyszko J; Pawlak K; Mysliwiec M
Int J Clin Lab Res; 1996; 26(3):199-202. PubMed ID: 8905452
[TBL] [Abstract][Full Text] [Related]
32. Influence of long-term erythropoietin treatment on plasma levels of calcium-phosphate related hormones in haemodialyzed uraemic patients.
Kokot F; Wiecek A; Marcinkowski W; Schmidt-Gayk H; Rudka R; Trembecki J
Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():9-16. PubMed ID: 8192535
[TBL] [Abstract][Full Text] [Related]
33. Erythropoietin potentiates thrombus development in a canine arterio-venous shunt model.
Wolf RF; Gilmore LS; Friese P; Downs T; Burstein SA; Dale GL
Thromb Haemost; 1997 May; 77(5):1020-4. PubMed ID: 9184421
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregation in hemodialysis patients.
el-Shahawy MA; Francis R; Akmal M; Massry SG
Clin Nephrol; 1994 May; 41(5):308-13. PubMed ID: 8050212
[TBL] [Abstract][Full Text] [Related]
35. Platelet membrane fluidity and intraplatelet Ca2+ homeostasis are affected in uremia.
Walkowiak B; Koziołkiewicz W; Michalec L; Borkowska E; Cierniewski CS
Pol J Pharmacol; 1996; 48(3):299-302. PubMed ID: 9112666
[TBL] [Abstract][Full Text] [Related]
36. Increase of plasma and red blood cell vitamin E concentration in uraemic patients on maintenance haemodialysis undergoing treatment with recombinant erythropoietin.
Paskalev D; Jankova T; Tschankova P; Steiner M; Nenov D
Nephrol Dial Transplant; 1993; 8(10):1187-8. PubMed ID: 8272244
[No Abstract] [Full Text] [Related]
37. High doses of recombinant erythropoietin stimulate platelet production in mice.
McDonald TP; Cottrell MB; Clift RE; Cullen WC; Lin FK
Exp Hematol; 1987 Jul; 15(6):719-21. PubMed ID: 3595770
[TBL] [Abstract][Full Text] [Related]
38. Parallel reduction of calcium-influx-dependent vasoconstriction and platelet-free calcium concentration with calcium entry and beta-adrenoceptor blockade.
Bolli P; Erne P; Hulthén UL; Ritz R; Kiowski W; Ji BH; Bühler FR
J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S996-1001. PubMed ID: 6085391
[TBL] [Abstract][Full Text] [Related]
39. Mechanism involved in the antiplatelet activity of naloxone in human platelets.
Sheu JR; Hung WC; Lee LW; Chang PT; Kan YC; Yen MH
Biochem Biophys Res Commun; 1997 Feb; 231(1):12-6. PubMed ID: 9070210
[TBL] [Abstract][Full Text] [Related]
40. N-acetyl cysteine attenuates ethanol induced hypertension in rats.
Vasdev S; Mian T; Longerich L; Prabhakaran V; Parai S
Artery; 1995; 21(6):312-6. PubMed ID: 8833231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
